Imatinib discontinuation for hypereosinophilic syndrome harboring the FIP1L1-PDGFRA transcript

Leuk Lymphoma. 2016;57(3):708-10. doi: 10.3109/10428194.2015.1065983. Epub 2015 Oct 2.

Authors

Grzegorz Helbig¹, Anna Soja¹, Alina Świderska², Marek Hus³, Sławomira Kyrcz-Krzemień¹

Affiliations

¹ a School of Medicine in Katowice, Department of Hematology and Bone Marrow Transplantation , Silesian Medical University , Katowice , Poland .
² b Department of Hematology , Regional Hospital , Zielona Góra , Polan , and.
³ c Department of Hemato-Oncology and Bone Marrow Transplantation , Medical University , Lublin , Poland.

PMID: 26430910
DOI: 10.3109/10428194.2015.1065983

No abstract available

Publication types

Letter

MeSH terms

Humans
Hypereosinophilic Syndrome / drug therapy*
Hypereosinophilic Syndrome / genetics*
Hypereosinophilic Syndrome / mortality
Imatinib Mesylate / administration & dosage
Imatinib Mesylate / therapeutic use*
Oncogene Proteins, Fusion / genetics*
Protein Kinase Inhibitors / administration & dosage
Protein Kinase Inhibitors / therapeutic use*
Receptor, Platelet-Derived Growth Factor alpha / genetics*
Recurrence
Treatment Outcome
mRNA Cleavage and Polyadenylation Factors / genetics*

Substances

Oncogene Proteins, Fusion
Protein Kinase Inhibitors
mRNA Cleavage and Polyadenylation Factors
Imatinib Mesylate
FIP1L1-PDGFRA fusion protein, human
Receptor, Platelet-Derived Growth Factor alpha